DE122007000033I1 - Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln - Google Patents

Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln

Info

Publication number
DE122007000033I1
DE122007000033I1 DE200712000033 DE122007000033C DE122007000033I1 DE 122007000033 I1 DE122007000033 I1 DE 122007000033I1 DE 200712000033 DE200712000033 DE 200712000033 DE 122007000033 C DE122007000033 C DE 122007000033C DE 122007000033 I1 DE122007000033 I1 DE 122007000033I1
Authority
DE
Germany
Prior art keywords
disassembled
particles
producing
human papillomavirus
papillomavirus vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE200712000033
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122007000033(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE122007000033I1 publication Critical patent/DE122007000033I1/de
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20023Virus like particles [VLP]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/10Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE200712000033 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln Pending DE122007000033I1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles
PCT/US2000/007595 WO2000057906A1 (en) 1999-03-26 2000-03-22 Human papillomavirus vaccine with disassembled and reassembled virus-like particles

Publications (1)

Publication Number Publication Date
DE122007000033I1 true DE122007000033I1 (de) 2007-08-09

Family

ID=26824774

Family Applications (4)

Application Number Title Priority Date Filing Date
DE200712000034 Pending DE122007000034I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln
DE200712000033 Pending DE122007000033I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln
DE60030698T Expired - Lifetime DE60030698T2 (de) 1999-03-26 2000-03-22 Verfahren zur herstellung eines human-papillomavirus-vakzins mit disassemblierten und reassemblierten virus-aehnlichen partikeln
DE200712000032 Pending DE122007000032I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und Reassembliertenn Virusaehnlichen Partikeln

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE200712000034 Pending DE122007000034I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und ReassembliertenVirusaehnlichen Partikeln

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE60030698T Expired - Lifetime DE60030698T2 (de) 1999-03-26 2000-03-22 Verfahren zur herstellung eines human-papillomavirus-vakzins mit disassemblierten und reassemblierten virus-aehnlichen partikeln
DE200712000032 Pending DE122007000032I1 (de) 1999-03-26 2000-03-22 Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und Reassembliertenn Virusaehnlichen Partikeln

Country Status (19)

Country Link
US (2) US6245568B1 (de)
EP (1) EP1165126B1 (de)
JP (1) JP4594534B2 (de)
KR (1) KR20020013516A (de)
AR (1) AR023166A1 (de)
AT (1) ATE339222T1 (de)
AU (1) AU778937B2 (de)
CA (1) CA2368391C (de)
CY (4) CY1105779T1 (de)
DE (4) DE122007000034I1 (de)
DK (1) DK1165126T3 (de)
ES (1) ES2270822T3 (de)
FR (1) FR07C0026I2 (de)
LT (1) LTC1165126I2 (de)
LU (3) LU91326I2 (de)
NL (3) NL300268I1 (de)
PT (1) PT1165126E (de)
SI (1) SI1165126T1 (de)
WO (1) WO2000057906A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
EP1250593B1 (de) * 1999-12-09 2009-03-25 Medimmune, Inc. In-vitro-methode zur zerlegung und zum wiederzusammenfügen von papillomavirusartigen partikeln
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
WO2003009869A1 (en) * 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2003068163A2 (en) * 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
MY132859A (en) 2002-11-01 2007-10-31 Glaxosmithkline Biologicals Sa Immunogenic composition
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
DK1572233T3 (da) 2002-12-20 2011-06-27 Glaxosmithkline Biolog Sa Anvendelse af HPV16 og HPV18 som vaccine mod et eller flere onkogene HPV-vira af typerne 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
EP1785433A4 (de) * 2004-07-01 2008-10-01 Tokyo Inst Tech Viruspartikelähnliches konstrukt und verfahren zu dessen bildung unter physiologischen bedingungen
EP1841474A2 (de) * 2005-01-25 2007-10-10 Wyeth Research Ireland Limited Verfahren zur diafiltrierung
JP2009501520A (ja) * 2005-07-14 2009-01-22 メイヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ パラミクソウイルス科ウイルス調製物
US20090105130A1 (en) * 2005-08-12 2009-04-23 Astellas Pharma Inc. Depsipeptide-containing injection solution
WO2007027076A1 (es) * 2005-09-01 2007-03-08 Nuno Ayala Jose Luis Formula estabilizadora de vacunas con antígenos vivos para su uso en sistemas de vacunación masiva
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US8962262B2 (en) * 2006-05-11 2015-02-24 Arbor Vita Corporation Method of protein extraction from cells
US9207240B2 (en) * 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
EP2258380B1 (de) * 2008-03-31 2013-03-13 Morinaga Milk Industry Co., Ltd. Nukleinsäure zur erhöhung der wärmeresistenz von lactoferrin
DK2473596T3 (en) * 2009-09-03 2018-01-22 Becton Dickinson Co METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS
PL2608805T3 (pl) 2010-08-23 2017-12-29 Wyeth Llc Trwałe preparaty antygenów rLP2086 Neisseria meningitidis
CN103096920B (zh) 2010-09-10 2016-03-23 惠氏有限责任公司 脑膜炎奈瑟球菌orf2086抗原的非脂质化变体
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人***状瘤病毒的接种方法
KR101559622B1 (ko) 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
KR102199096B1 (ko) 2013-09-08 2021-01-06 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
EP3270959A1 (de) 2015-02-19 2018-01-24 Pfizer Inc Neisseria meningitidis-zusammensetzungen und verfahren dafür
EP3577130A2 (de) 2017-01-31 2019-12-11 Pfizer Inc Neisseria meningitidis-zusammensetzungen und verfahren dafür
US20200010850A1 (en) 2017-02-17 2020-01-09 The USA, as represeented by the Secretary, Dept. of Health and Human Services Efficient cell free production of papillomavirus gene transfer vectors
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034594A1 (en) * 1997-02-06 1998-08-13 Merck & Co., Inc. Thimerosal-free preservatives for vaccines
NZ500028A (en) 1997-04-08 2001-08-31 Merck & Co Inc Stabilized human papillomavirus formulations also containing a salt and a nonionic surfactant
AU755679B2 (en) 1997-07-03 2002-12-19 Medimmune, Llc Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture,and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
DE60030698D1 (de) 2006-10-26
PT1165126E (pt) 2006-12-29
NL300268I1 (nl) 2007-05-01
CA2368391C (en) 2011-06-07
LU91328I9 (de) 2019-03-01
EP1165126A1 (de) 2002-01-02
CY2007010I1 (el) 2009-11-04
NL300269I2 (nl) 2008-07-01
CA2368391A1 (en) 2000-10-05
LTPA2007002I1 (lt) 2020-03-25
AU3909300A (en) 2000-10-16
LU91327I2 (fr) 2007-05-14
LTC1165126I2 (lt) 2020-04-27
US20010021385A1 (en) 2001-09-13
FR07C0026I1 (de) 2007-04-27
SI1165126T1 (sl) 2006-12-31
LU91327I9 (de) 2019-03-01
DE122007000032I1 (de) 2007-08-09
US6245568B1 (en) 2001-06-12
LU91326I2 (fr) 2007-05-14
CY2007010I2 (el) 2009-11-04
NL300269I1 (nl) 2007-05-01
ATE339222T1 (de) 2006-10-15
CY1105779T1 (el) 2010-07-28
LU91326I9 (de) 2018-12-31
JP4594534B2 (ja) 2010-12-08
FR07C0026I2 (fr) 2012-08-03
JP2002540167A (ja) 2002-11-26
LU91328I2 (fr) 2007-05-14
EP1165126B1 (de) 2006-09-13
AU778937B2 (en) 2004-12-23
AR023166A1 (es) 2002-09-04
CY2007008I2 (el) 2009-11-04
NL300270I1 (nl) 2007-05-01
WO2000057906A1 (en) 2000-10-05
ES2270822T3 (es) 2007-04-16
CY2007008I1 (el) 2009-11-04
CY2007009I2 (el) 2010-07-28
DE122007000034I1 (de) 2007-08-09
DK1165126T3 (da) 2007-01-08
CY2007009I1 (el) 2010-07-28
KR20020013516A (ko) 2002-02-20
DE60030698T2 (de) 2007-07-19

Similar Documents

Publication Publication Date Title
DE122007000032I1 (de) Verfahren zur Herstellung eines Human-Papillomavirusvakzins mit Disassemblierten und Reassembliertenn Virusaehnlichen Partikeln
DE60141806D1 (de) Silikongummi in form eines feinverteilten puders sowie verfahren zur herstellung und verwendung desselben
DE60237932D1 (de) Verfahren und Vorrichtung zur Herstellung eines künstlichen Sprudelwassers
DE60028870D1 (de) Verfahren und Vorrichtung zur Herstellung eines zweiteiligen Kolbens
DE60111165D1 (de) Verfahren zur Herstellung eines Glasmatrixverbundwerkstoffes und Glasmatrixverbundwerkstoff
DE60218386D1 (de) Verfahren und System zur Erstellung eines dentalen Modells mittels Bildgebung
DE50207943D1 (de) Kristallines anticholinergikum, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
DE50001218D1 (de) Vorrichtung und verfahren zur generativen herstellung eines dreidimensionalen objektes
DE60326329D1 (de) Verfahren zur herstellung eines keramikwabenstrukturkörpers und keramikwabenstrukturkörper
DE60204022D1 (de) Verfahren zur herstellung eines poly(arylenether)s und danach hergestellter poly(arylenether)
DE60319099D1 (de) Kaugummiformulierung und verfahren zur herstellung derselben
DE69912998D1 (de) Herzklappe und verfahren zu herstellung eines biologischen gewebes
DE60120346D1 (de) Verfahren und Vorrichtung zur Herstellung eines gefriergetrockneten Produktes
TWI349557B (en) Use of hpv 16 and hpv 18 vlps for vaccine preparation
AU2003271021A1 (en) Immunogen for preparation of therapeutic vaccines or drugs for treatment of hepatitis b and the producing method and use thereof
DE60102862T2 (de) Verfahren zur herstellung eines feuerdetektors und feuerdetektor
EP1694694A4 (de) Replikationskompetentes hepatitis-c-virus und anwendungsverfahren
DE50208869D1 (de) Verfahren und vorrichtung zur herstellung eines zylinderförmigen glaskörpers
DE60140735D1 (de) Methode zur herstellung von ito-pulver mit in indiumoxid gelöstem zinn und verfahren zur herstellung eines ito-targets
DE60000465D1 (de) Verfahren und Vorrichtung zur Herstellung eines Verbundmaterials
DE50115727D1 (de) Piezoaktor und verfahren zur herstellung eines piezoaktors
EP1651258A4 (de) Hepatitis virus kern-proteine als vakzine-plattformen und anwendungsverfahren dafür
DE60116275D1 (de) Verfahren zur herstellung eines titansilicalitformkörpers
ATE380034T1 (de) Neues verfahren zur herstellung von virus- ähnlichen partikeln des menschen-papillomavirus mit verbesserten eigenschaften
DE60324030D1 (de) Vorrichtung zur herstellung eines metallrohrs mit ovalem querschnitt und herstellungsverfahren